Effect of Clofarabine on Apoptosis and DNA Synthesis in Human Epithelial Colon Cancer Cells

Autor: F. Albertioni, Xin Wang

Publikováno v: Nucleosides, Nucleotides and Nucleic Acids. 29:414-418

Clofarabine, a new-generation purine nucleoside analogue, was thought to work via three mechanisms: incorporation into DNA; induction of apoptosis; and inhibition of ribonucleotide reductase, and showed significant efficacy in pediatric relapsed/refr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5b5a488405e9400d3fe0798415a3965
https://doi.org/10.1080/15257771003738568

The PPP2R1A cancer hotspot mutant p.R183W increases clofarabine resistance in uterine serous carcinoma cells by a gain-of-function mechanism.

Autor: Remmerie M; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Gasthuisberg O&N1, Herestraat 49, PO-box 901, Leuven, B-3000, Belgium.; KU Leuven Cancer Institute (LKI), Leuven, B-3000, Belgium., Dok R; KU Leuven Cancer Institute (LKI), Leuven, B-3000, Belgium.; Laboratory of Experimental Radiotherapy, Department of Oncology, University of Leuven (KU Leuven), Leuven, B-3000, Belgium., Wang Z; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven), Leuven, B-3000, Belgium., Omella JD; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Gasthuisberg O&N1, Herestraat 49, PO-box 901, Leuven, B-3000, Belgium.; KU Leuven Cancer Institute (LKI), Leuven, B-3000, Belgium., Alen S; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Gasthuisberg O&N1, Herestraat 49, PO-box 901, Leuven, B-3000, Belgium., Cokelaere C; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Gasthuisberg O&N1, Herestraat 49, PO-box 901, Leuven, B-3000, Belgium.; KU Leuven Cancer Institute (LKI), Leuven, B-3000, Belgium., Lenaerts L; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Gasthuisberg O&N1, Herestraat 49, PO-box 901, Leuven, B-3000, Belgium., Dreesen E; Clinical Pharmacology and Pharmacotherapy, Department of Pharmaceutical and Pharmacological Sciences, University of Leuven (KU Leuven), Leuven, B-3000, Belgium., Nuyts S; KU Leuven Cancer Institute (LKI), Leuven, B-3000, Belgium.; Laboratory of Experimental Radiotherapy, Department of Oncology, University of Leuven (KU Leuven), Leuven, B-3000, Belgium., Derua R; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Gasthuisberg O&N1, Herestraat 49, PO-box 901, Leuven, B-3000, Belgium.; SybioMA, Proteomics Core Facility, University of Leuven (KU Leuven), Leuven, B-3000, Belgium., Janssens V; Laboratory of Protein Phosphorylation and Proteomics, Department of Cellular and Molecular Medicine, University of Leuven (KU Leuven), Gasthuisberg O&N1, Herestraat 49, PO-box 901, Leuven, B-3000, Belgium. veerle.janssens@kuleuven.be.; KU Leuven Cancer Institute (LKI), Leuven, B-3000, Belgium. veerle.janssens@kuleuven.be.

Publikováno v: Cellular oncology (Dordrecht, Netherlands) [Cell Oncol (Dordr)] 2024 Oct; Vol. 47 (5), pp. 1811-1829. Date of Electronic Publication: 2024 Jun 18.

Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia

Autor: K Wallman, G Tjønnfjord, C M Stolt, M Hedenus, D Heldal, E Hippe, F Albertioni, Stein A. Evensen, Gunnar Juliusson, Claes Malm

Publikováno v: Journal of Clinical Oncology. 13:989-995

PURPOSE To evaluate the clinical efficacy and safety of 2-chlorodeoxyadenosine (CdA) when administered by subcutaneous injection to patients with symptomatic hairy cell leukemia (HCL), and to evaluate predictive factors for response. PATIENTS AND MET

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::99c3f0adf146f6c05c76425c65f961e0
https://doi.org/10.1200/jco.1995.13.4.989

On the bioavailability of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration

Autor: F. Albertioni, Jan Liliemark, Moustapha Hassan, Gunnar Juliusson

Publikováno v: Journal of Clinical Oncology. 10:1514-1518

PURPOSE The antimetabolite 2-chloro-2'-deoxyadenosine (CdA) is a promising alternative to alkylating agents for the treatment of lymphoproliferative disorders. Its use, however, is hampered by the need for intravenous (IV) administration. The aim of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::55c8bae53a30d0d8a0a4b9c95434db6e
https://doi.org/10.1200/jco.1992.10.10.1514

Pharmacological basis for cladribine resistance in a human acute T lymphoblastic leukaemia cell line selected for resistance to etoposide

Autor: K, Lotfi, E, Månsson, J, Chandra, Y, Wang, D, Xu, E, Knaust, T, Spasokoukotskaja, E, Liliemark, S, Eriksson, F, Albertioni

Publikováno v: British journal of haematology. 113(2)

Cross-resistance between different classes of anti-neoplastic agents can jeopardize successful combination cancer chemotherapy. In this study, we observed an unexpected cross-resistance between the podophyllotoxine derivative etoposide (VP) and the n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::e7c051a4f43b5cc8a08517bf87e02ed2
https://pubmed.ncbi.nlm.nih.gov/11380397